Pro Medicus Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $45.12
- Today's High:
- $45.12
- Open Price:
- $45.12
- 52W Low:
- $32.3977
- 52W High:
- $47.6088
- Prev. Close:
- $45.12
- Volume:
- 60
Company Statistics
- Market Cap.:
- $4.85 billion
- Book Value:
- 1.329
- Revenue TTM:
- $124.90 million
- Operating Margin TTM:
- 67.32%
- Gross Profit TTM:
- $126.79 million
- Profit Margin:
- 48.56%
- Return on Assets TTM:
- 29.26%
- Return on Equity TTM:
- 50.43%
Company Profile
Pro Medicus Limited had its IPO on under the ticker symbol PMCUF.
The company operates in the Healthcare sector and Health Information Services industry. Pro Medicus Limited has a staff strength of 0 employees.
Stock update
Shares of Pro Medicus Limited opened at $45.12 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $45.12 - $45.12, and closed at $45.12.
This is a 0% increase from the previous day's closing price.
A total volume of 60 shares were traded at the close of the day’s session.
In the last one week, shares of Pro Medicus Limited have slipped by -1.59%.
Pro Medicus Limited's Key Ratios
Pro Medicus Limited has a market cap of $4.85 billion, indicating a price to book ratio of 60.5969 and a price to sales ratio of 41.3245.
In the last 12-months Pro Medicus Limited’s revenue was $124.90 million with a gross profit of $126.79 million and an EBITDA of $84.37 million. The EBITDA ratio measures Pro Medicus Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pro Medicus Limited’s operating margin was 67.32% while its return on assets stood at 29.26% with a return of equity of 50.43%.
In Q2, Pro Medicus Limited’s quarterly earnings growth was a positive 40.6% while revenue growth was a positive 38.4%.
Pro Medicus Limited’s PE and PEG Ratio
- Forward PE
- 93.4579
- Trailing PE
- 125.3333
- PEG
Its diluted EPS in the last 12-months stands at $0.36 per share while it has a forward price to earnings multiple of 93.4579 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pro Medicus Limited’s profitability.
Pro Medicus Limited stock is trading at a EV to sales ratio of 43.9019 and a EV to EBITDA ratio of 58.8794. Its price to sales ratio in the trailing 12-months stood at 41.3245.
Pro Medicus Limited stock pays annual dividends of $0.3 per share, indicating a yield of 0.48% and a payout ratio of 43.1%.
Balance sheet and cash flow metrics
- Total Assets
- $202.14 million
- Total Liabilities
- $30.85 million
- Operating Cash Flow
- $-6685000.00
- Capital Expenditure
- $51500
- Dividend Payout Ratio
- 43.1%
Pro Medicus Limited ended 2024 with $202.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $202.14 million while shareholder equity stood at $138.78 million.
Pro Medicus Limited ended 2024 with $0 in deferred long-term liabilities, $30.85 million in other current liabilities, 1959000.00 in common stock, $127.12 million in retained earnings and $0 in goodwill. Its cash balance stood at $91.25 million and cash and short-term investments were $121.50 million. The company’s total short-term debt was $654,000 while long-term debt stood at $0.
Pro Medicus Limited’s total current assets stands at $163.79 million while long-term investments were $0 and short-term investments were $30.25 million. Its net receivables were $39.88 million compared to accounts payable of $1.03 million and inventory worth $55000.00.
In 2024, Pro Medicus Limited's operating cash flow was $-6685000.00 while its capital expenditure stood at $51500.
Comparatively, Pro Medicus Limited paid $0.43 in dividends in 2024.
Other key metrics
- Current Trading Price
- $45.12
- 52-Week High
- $47.6088
- 52-Week Low
- $32.3977
- Analyst Target Price
- $
Pro Medicus Limited stock is currently trading at $45.12 per share. It touched a 52-week high of $47.6088 and a 52-week low of $47.6088. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $43.45 and 200-day moving average was $37.12 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5397.3% of the company’s stock are held by insiders while 1195.1% are held by institutions.
Frequently Asked Questions About Pro Medicus Limited
Similar Industry Stocks (Health Information Services)
Most Active
Top Gainers
Top Losers
About
Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.